CN Healthy Food Tech Group Corp. (UCFI) Stock Score, Valuation & Financial Research

CN Healthy Food Tech Group Corp. is in the Financial Services sector and Shell Companies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for UCFI

CN Healthy Food Tech Group Corp. does not currently have a complete Wall Street Score. The stored market price is USD 5.51. These figures are a research snapshot, not a buy or sell recommendation.

What CN Healthy Food Tech Group Corp. does

CN Healthy Food Tech Group Corp., based in Toluca Lake, California, specializes in the innovation, creation, and commercialization of advanced food biotechnology and wellness products. The company's operations encompass thorough research and development, manufacturing, and distribution, serving markets across Asia and around the world.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

CN Healthy Food Tech Group Corp. operates in the health and wellness food industry, focusing on the research, development, production, and sale of bio-health food products. The company generates revenue through two primary business segments: wholesale distribution of its grain-based health food products and direct-to-consumer sales via live-stream platforms.

Products and services

  • Natural, grain-based health foods and bio-health food products designed to support preventative health and wellness.

Customer types

Wholesale distributors; Direct-to-consumer retail customers.

Suppliers, materials and equipment

  • Unnamed raw material and ingredient suppliers — The company relies on various third-party suppliers for the raw materials and ingredients used in its bio-health food production. Source

Business strengths to evaluate

  • Integration of modern biotechnology with traditional Chinese medicine theory Source

Business risks and research considerations

  • Operational risks associated with reliance on third-party production and supply chain counterparties Source

Sources: Company research source · Integration of modern biotechnology with traditional Chinese medicine theory

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

UCFI financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.51
Market capitalization:
287.87M (currency not supplied)
Revenue:
USD 21.61M
Net income:
USD 4.34M
Free cash flow:
USD -9.8M
Cash:
USD 29.69M
Total debt:
USD 4.02M
EPS:
USD 0.08
P/E ratio:
66.6x

What stands out

  • Reported year-over-year revenue growth is -22.2%.
  • Free cash flow is USD -9.8M, negative for the stored period.
  • The balance sheet shows USD 29.69M of cash versus USD 4.02M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -45.3% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals 20.1% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 25.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for UCFI

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving UCFI's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can UCFI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is UCFI likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of UCFI's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research UCFI

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.